Search Results
Jul 21, 2026, 10:54 ET Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
428-438.Definium Therapeutics, "Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder," press release, June 22, 2026.Rush AJ, Trivedi MH, Wisniewski SR, et al. (2006). Acute and long-term outcomes
More news about: Helus Pharma
Jul 21, 2026, 10:31 ET Acute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsight
ZYNRELEF, COMBOGESIC, INVELTYS, UBRELVY, LOTEMAX SM, DEXTENZA, TOSYMRA, ZEMBRACE SYMTOUCH, ONZETRA XSAIL, BREKIYA, ATZUMI, REYVOW, ZAVZPRET, NURTEC ODT/VYDURA, EMGALITY, ELYXYB, TRUDHESA, SYMBRAVO, APP13007, and othersScope of the Acute Pain Market Report
More news about: DelveInsight Business Research, LLP
Jul 17, 2026, 08:50 ET Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
it.Definium Therapeutics, Inc. (NASDAQ: DFTX), formerly Mind Medicine, carries the deepest late-stage pipeline in the group. Lead candidate DT120 ODT, an orally disintegrating tablet of lysergide tartrate previously known as MM120, is in five Phase 3 studies spanning generalized anxiety disorder, major
More news about: USA News Group
Jun 26, 2026, 09:30 ET A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
primary-endpoint disclosures, 2025–2026.[3] Definium Therapeutics, Inc. (Nasdaq: DFTX), "Positive Topline Results from Phase 3 Emerge Study of DT120 ODT in MDD" and "Pricing of $700 Million Upsized Public Offering," June 2026.[4] GH Research PLC (Nasdaq: GHRS), corporate and clinical-program
More news about: USA News Group
Jun 04, 2026, 10:01 ET Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
prevalence of the disease, advancements in diagnostic tools, heightened patient awareness, growing investments in innovative therapies such as DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies,
More news about: DelveInsight Business Research, LLP
May 06, 2026, 06:00 ET CLEAR Announces First Quarter 2026 Financial Results
the live webcast https://event.choruscall.com/mediaframe/webcast.html?webcastid=T4Fd6odt. A webcast replay will be available after the event on the investor relations website at
More news about: CLEAR
Mar 23, 2026, 08:00 ET OFD Life Sciences Awarded Patent for Breakthrough Innovation in ODT Manufacturing
multimedia:https://www.prnewswire.com/news-releases/ofd-life-sciences-awarded-patent-for-breakthrough-innovation-in-odt-manufacturing-302720083.htmlSOURCE
More news about: OFD Life Sciences
Mar 22, 2026, 22:39 ET Longsys präsentiert auf der Embedded World 2026 KI-gestützte Speicherlösungen
WM7400/7300/7200-Controller integrierenLPDDR4x in Automobilqualität: 4266 Mbps Datenrate zur Verbesserung des KI-Cockpit-Erlebnisses mit integrierter ODT- und DQS-TechnologieKI-Roboterlösungen ermöglichen Embodied IntelligenceAngesichts der wachsenden Nachfrage im Bereich Embodied
More news about: Longsys
Mar 15, 2026, 22:27 ET Longsys presentó soluciones de almacenamiento basadas en IA en Embedded World 2026
propio.Memoria LPDDR4x de grado automotriz: Velocidad de datos de 4266 Mbps que mejora la experiencia de la cabina de IA con tecnología ODT y DQS integradas.Las soluciones de robótica con IA permiten la inteligencia incorporadaPara responder a la creciente demanda
More news about: Longsys
Mar 15, 2026, 22:25 ET Longsys présente ses solutions de stockage optimisées par l'IA à l'Embedded World 2026
développés en interne.LPDDR4x de qualité automobile : débit de données de 4 266 Mo/s améliorant les expériences IA grâce à la technologie ODT et DQS intégréeLes solutions de robots d'IA permettent l'intelligence incarnéePour répondre à la demande croissante en matière
More news about: Longsys
Mar 13, 2026, 08:13 ET Longsys Showcased AI-Driven Storage Solutions at Embedded World 2026
self-developed WM7400/7300/7200 controllersAutomotive-grade LPDDR4x: 4266Mbps data rate enhancing AI cockpit experiences with integrated ODT and DQS technologyAI Robot Solutions Enable Embodied IntelligenceAddressing growing demand in embodied intelligence, Longsys
More news about: Longsys
Mar 09, 2026, 10:50 ET CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
sufficient to fund operations into 2028. The company rebranded in January 2026 to reflect its focus on a late-stage psychiatry pipeline anchored by DT120 ODT, a lysergide tartrate compound that holds FDA Breakthrough Therapy Designation for generalized anxiety disorder."With our first Phase 3 MDD trial,
More news about: USA News Group
Feb 26, 2026, 11:10 ET Comienza en México la preventa de la nueva serie Galaxy S26
https://mma.prnewswire.com/media/2920788/ODT_B083_PreOrder_KVS26Ultra_1920x1080_2_e1772044073871.jpg
More news about: Samsung Mexico
Feb 11, 2026, 11:44 ET ¡Galaxy Unpacked está por llegar! Pre-Regístrate con Samsung México y obtén increíbles beneficios
https://mma.prnewswire.com/media/2902233/ODT_B059_KV_HR_MIRACLE_VF_1000_e1770772916464.jpg
More news about: Samsung Mexico
Feb 10, 2026, 19:25 ET Galaxy Unpacked febrero 2026: el verdadero teléfono de IA hace tu vida más fácil
https://mma.prnewswire.com/media/2901671/ODT_B046_UnpackedMiracle_1920x1080.jpg
More news about: Samsung Mexico
Jan 12, 2026, 12:00 ET PremierOne Credit Union Introduces a Digital Estate Planning Solution
access to a subscription-based digital estate planning tool, available through a partnership between TruStage™ and One Digital Trust (ODT), a leading provider of online estate planning solutions.
More news about: PremierOne Credit Union
Oct 23, 2025, 09:21 ET METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
novel oral formulation designed for the treatment of PBA, utilizing METiS TechBio's proprietary AiTEM platform to develop orally disintegrating tablet (ODT). Tailored for patients frequently experiencing dysphagia, MTS-004 dissolves rapidly in the mouth without the need for water, offering a pleasant taste
More news about: METiS TechBio
Sep 24, 2025, 17:31 ET Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight
(VNX001), BHV-2100, and others.By 2034, among all the therapies, the highest revenue is expected to be generated by NURTEC ODT/VYDURA (rimegepant), a CGRP receptor antagonist.Discover which therapies are expected to grab the major moderate-to-severe acute pain treatment
More news about: DelveInsight Business Research, LLP